TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Visual field progression using visual field index (VFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual field progression using the guided progression analysis (GPA) strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of the Critical-Care Pain Observation Tool (CPOT) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of the bispectral Index (BIS) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Power spectral density (PSD) of monoamine metabolite measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perfusion index of cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in Miller score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time interval for DBSs to be visually identical with T4/T1 ratio > 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of infant dyschezia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of infant colic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of physiotherapy treatments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cumulative incidence of ventilator-associated lower respiratory tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Surrogate lipid markers of cardiovascular disease (CVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants transplanted
Endpoint domain: Mortality/survival
Primary endpoint: Clinical benefit (CB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provocative Concentration (PC) of Adenosine 5' Monophosphate (AMP) Causing a 20 Percent (%) Reduction in Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cortisol Suppression 0-24 Hours Weighted Mean
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Assessment of Overall Image Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or Absence of Abnormal 64Cu-DOT-ECL1i Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCR2 Detection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary calcium oxalate supersaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Calcium phosphate supersaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Predictive accuracy of clinical diagnosis of hypotonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of orofacial cleft
Endpoint domain: Mortality/survival
Primary endpoint: Level of Substance-P
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of neurokinin-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of Calcitonin gene-related peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Self-management
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Patient activation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Endoscopic gastric varices eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Endoscopic esophageal varices aggravation/resolution rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric varices rebleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tooth shade value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of DLT (Dose limit toxicity)
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of clinical stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of alcohol consumption
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Decrease in the frequency of migraine headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Communicative behaviour of dental nurse
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: HbA1c, Glycated Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS Pain Score - Immediate Post-Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AEs), Serious AEs and AEs of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Dependence assessed by the modified Rankin scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under Plasma Concentration Time Curve (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who experienced dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) and/or recommend Phase II dose (RP2D) of INCB7839
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of diagnosis of bacterial pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total oocyte number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clinical pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selected parameters of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Total Score of the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Showing Improvement for Each Domain of Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of children with MRSA and MSSA carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of children with MRSA and MSSA skin and soft tissue infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in blood spot phenylalanine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blood spot tyrosine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in adherence to study product intake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participants' gastrointestinal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in plasma amino acid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variation of Lipid parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Keratitis healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient perception of colonoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline of the hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of the percentage of terminal hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of the percentage of vellus hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of hair regrowth speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mortality rate after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Change of interincisal distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of [18F]NOS and Florbetaben
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants walking independently
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in axial length elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oncologic outcomes associated with biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immunologic biomarkers for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunologic biomarkers for prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Neural Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of dose-limited toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Percent Change From Baseline in MADRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Late Positive Potential to Rewarding Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Reward Positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in P1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Behavioral Activation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pericranial muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Event of Adjudicated Cardiovascular Death
Endpoint domain: Mortality/survival
Primary endpoint: Time to First Event of Adjudicated Hospitalisation for Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of acute wound healing complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of successful MRI scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-adjusted clinical and parasitological cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uNGAL measurement as an early detector of CIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Plasma Glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in maximal oxygen consumption (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical Device Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Treatment-emergent AEs (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Sotorasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline Modified Medical Research Council scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline University of California, San Diego Shortness of Breath Questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-specific overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Marijuana Use
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported dietary intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intelligence quotient (IQ) at 3.5 years
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants in Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants in Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of continuous SpHb measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Early Allograft Dysfunction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irradiated GI mucosa health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total RBC loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Composite of death, graft loss and renal failure
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events related to the stent insertion
Endpoint domain: Adverse events/effects
Primary endpoint: Speed-thresholds performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glasgow-Pittsburgh Cerebral Performance Categories (CPC)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Weekly Substance Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dropout rate during the internet-based recruitment procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who completed at least 6 out of 8 modules
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Client satisfaction on the Client Satisfaction Questionnaire-8 (CSQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Brief Observation of Social Communication Change (BOSCC)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change From Baseline in Triglycerides, Total Cholesterol, LDL Cholesterol, HDL Cholesterol, and Serum Glucose at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Serum Lipase at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in AST and ALT at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary 11-Dehydrothromboxane B2 (11-dTxB2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vertical Bone Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Train-Of-Four (TOF)-Ratio <0.9 at Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: change in Eustachian tube function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in Care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of Participants With Immediate Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: For Toddlers: Serotype Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each Pneumococcal Serotype at 30 Days Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: For Infants: Percentage of Participants With Serotype Specific IgG Concentration >=0.35 mcg/mL 30 Days Post-Dose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accessibility to prophylactic and on-demand antihemorrhagic treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Colicky Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colicky Crying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Tract Infection Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Infection rate of multidrug-resistant organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: dialysis complication
Endpoint domain: Adverse events/effects
Primary endpoint: Altered Bowel Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient accrual per center
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinically-indicated Major Adverse Cardiac Events
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of subsurface laser in detecting cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Solithromycin levels in plasma and various fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants diagnosed with non-traumatic painful elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 Ordinal Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device and/or Procedure-Related Death or Myocardial Infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Any Target Lesion Revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Target Limb(s) Major Amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of ESR1 mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean value of stride time variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-acetylaspartate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Creatine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Receiver Operating Characteristics (AUROC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Longevity gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for opiate pain medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Drug Rating Questionnaire-Subject (DRQ-S), Question 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: haematological relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional outcome based on the Helkimo dysfunction index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Limb fat measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Positive and Negative Affect Scale (PANAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MEP and SSEP readings improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measured by visual analogy scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of recruitment and retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the P1-CaLL intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bone augmentation results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline Mini-Mental State Examination (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline Clinical Dementia Rating (CDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline Rey Auditory Verbal Learning Test (RAVLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hepatitis B S Antigen Decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean of serum low-density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resolution of vitreous hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Phosphene Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Organ failure free days
Endpoint domain: Mortality/survival
Primary endpoint: change of ANS flexibility at 2 months from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of cognition at 2 months from baseline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocyte phenotype - Tissue necrosis factor-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monocyte phenotype - Interferon-γ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes